Which of the following is not a pharmacological propey of Repaglinide?
Repaglinide: the first member of the group, was approved for clinical use in 1998. These drugs modulate B cell insulin release by regula ng potassium efflux through the potassium channels. It should be taken just before each meal in doses of 0.25-4 mg; hypoglycemia is a risk if the meal is delayed or skipped or contains inadequate carbohydrate.
All India exam
Insulin Secretagogues
Reduces insulin resistance
Causes less hypoglycemia than sulfonylureas
Effectively reduced postprandial hyperglycemia
Reduces insulin resistance